hyperparathyroidism.Matched p a i r s of 14 premature infants(birthweight1430g,980-1700g;~,range;gestational age33weeks,31-35wecks) were fed human milk with supplements of p h o s p h o~s ( P ) o r calcium+ P .VitanlinD 10001 .U./d were given.P,iPlll(midregional antibody) , 2501tD(RIA) ,?,25Dc(W) ,DBP(radial imunodiffusion) and alkaline phosphatase(AP) were measured i n serum a t bodyweights 1800+75g(I) and 2150+75g(II) ,respectively.Results were not significantly-different G t h i n p a i r s and therefore a r e indicated together a s x+SD:
17 5 H.Garah6dian*,R.RraunerX,R.Grimher~,C.Pr6vot*,R.Rappaport, In an attempt to better understand the control of plasma 1,25-(OH)2~ concentratims cbring puberty, these concentrations have been measured i n 12 g i r l s (age 3 yr 6 mo-8 yr 10 mo) w i t h central precocicus puherty hefore and after 3, 6, 9, 12, 18 and 24 months of treatment with a LHRH analowe (fluserelina, Hoechst). Mean and extreme values for 1,25-(OH)2~ were 76 pg/ml (5F114) before treatment, 68 pg/ml (43-107) and 45 pg/ml (26-87) after 12 and 18-24 months of treatment respectively. No correletion was found a t any time studied between plasma 1,25-(OH)2~ and : plasma estradiol, plasm DHAS, vaginal msturation index, hone age,hei@t gain (cm/year), plasm SmC/IGFI, serum calcium, phosphorus and alkaline phosphatase activity. Plasma 1,25(OH)2~ values were also not correlated with plasma basal LH and FSH hefore treatment, but were significantly correlated w i t h plasm hasal LH ( r : 0.67, p<0.02) and plasma basal FSH ( r m 0.71, p<0.01) after 12 months of treatment. ilTHfm1/1) 4 6~1 6 6 5~3 5
Frm these results, m e may speculate that the control of plasma 1,25-(OH)2~ &ring puherty i s not directly dependent upon skeletal grauth, skeletal maturation and ovarian secretion but could be, a t least partially, dependent upon central factors.
AP was normal i n a l l samples. Both 1 ,25Dc and FDI were high when compared t o adult reference values but occurred without hypophosphatemia o r hyperparathyroidism. The significance of high t o t a l and f r e e 1,2SDc i n prenlaturc inf a n t s and the mechanisms of i t s regulation remain t o be clucidated. The syndrome of 1,25(OH)2D r e s i s t a n t r i c k e t s and a l o~e c i a has been shown t o be caused 2 ; defective receotors t o the a c t i v e D-metabolite (ESPE, 1982; JCEM 55:1020 JCEM 55: , 1982 . In search of a therapeutic approach, 7 pa l e n t s aged 2-12 years were treated.
J ' .
On a megadose of 60 uq/m /day of la0HD f o r P months, serum 1,25(OH) 0 increased t o 1100-3000 pg/ml (normal , 20-80 pg/ml), but ric$e$s was not healed.
Treatment of 3 p a t i e n t s with 20 ug/m2/day of 24,25(OH)2n3.wi th serum 24,25(OH)2D3 of 6.2-14 n4/ml (normal 1.5-4 ng/ml) f a i l e d t o heal $he r i c k e t s . With combined treatment of 24,25(OH)2D3 ?nd 30 mg/m /day i.v. calcium, rickets was not healed.
Two children, 6 and 3 years old, received 70 mg/m2/day elementary calcium through an intracaval c a t h e t e r , and serum calcium was maintained a t 9.1-10 mg/dl. Bone pains and muscular weakness disappeared within a week.
Serum PTH and phosphatase normalized a f t e r I and 4 months, respectively. X-rays dewonstrated complete healing of the r a c h i t i c bone changes a f t e r 4 and 6 months, respectively, and the c h i l d r e n ' s qrowth accelerated t o 16.5 and 9.8 cmlyear, respectively. These observations indicate t h a t normalization of serum calcium i s s u f f i c i e n t f o r healing of rickets and growth, even in t h e absence of functioning 1,25(0H)2D3 receptors. In addition, t h e incorporation of C-thymidine i n t o PHA-stimulated lymphocytes of t h e patients was not reduced by 1,25-(OH) D unlike i n control lymphocytes. These ga4;ent.s were t r e a t e d with la-hydroxyvitamin D [la-OHD ] and calcium(Ca) l a c t a t e . Two p a t i e n t s responded t o 3 u$,/kg/day3 of la-OHD and 2 g/day of Ca l a c t a t e , and t h e i r blood chemistry and bone 3esions were normalized a f t e r 15 and 36 weeks of treatment. However, the most severe case responded only p a r t i a l l y t o 5 ug/kg/day of la-OHD and 2 g/day of Ca l a c t a t e .
The alopecia of the p a t i e n t s was nat improved by these treatments. m e s e r e s u l t s suggest t h a t high doses of la-OHD may be useful i n treatment of MDR I1 with alooecia, which ha& been reported
